Alembic Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated August 04, 2026, titled "Revised Press Release on the Unaudited Financial Results for the quarter ended30th June, 2026.".
Alembic Pharmaceuticals Limited Press Release Aug 04 2026
Filed with NSE · · 3 pages · English
Release
Alembic Pharmaceuticals Limited on 6ix
In the deck
Earlier from Alembic Pharmaceuticals
- Alembic Pharmaceuticals Limited Press Release Jul 28 2026
- Alembic Pharmaceuticals Limited Press Release Jul 18 2026
- Alembic Pharmaceuticals Limited Press Release Jun 26 2026
- Alembic Pharmaceuticals Limited Press Release Jun 19 2026
- Alembic Pharmaceuticals Limited Press Release Jun 12 2026
Later from Alembic Pharmaceuticals
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg.
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals